Cutter & CO Brokerage Inc. Cuts Holdings in Amarin Co. plc (NASDAQ:AMRN)

Cutter & CO Brokerage Inc. reduced its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 31.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 286,620 shares of the biopharmaceutical company’s stock after selling 132,881 shares during the quarter. Cutter & CO Brokerage Inc. owned 0.07% of Amarin worth $181,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of AMRN. Arkfeld Wealth Strategies L.L.C. purchased a new position in Amarin during the second quarter worth approximately $28,000. Significant Wealth Partners LLC lifted its position in shares of Amarin by 128.7% during the 1st quarter. Significant Wealth Partners LLC now owns 34,582 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 19,461 shares in the last quarter. Algert Global LLC acquired a new stake in Amarin in the 2nd quarter valued at $34,000. Prospect Financial Services LLC purchased a new stake in Amarin in the 2nd quarter worth $41,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Amarin by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 29,992 shares during the period. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Amarin Price Performance

Shares of Amarin stock opened at $0.61 on Wednesday. The business has a 50 day simple moving average of $0.60 and a two-hundred day simple moving average of $0.72. The stock has a market capitalization of $251.37 million, a P/E ratio of -7.65 and a beta of 1.92. Amarin Co. plc has a 12 month low of $0.56 and a 12 month high of $1.37.

Insider Buying and Selling

In other Amarin news, CEO Aaron Berg bought 160,000 shares of the stock in a transaction on Friday, August 2nd. The shares were bought at an average price of $0.64 per share, with a total value of $102,400.00. Following the purchase, the chief executive officer now directly owns 805,380 shares in the company, valued at $515,443.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.96% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Amarin from a “buy” rating to a “hold” rating in a research note on Thursday, July 4th.

Amarin Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.